IPO registrations (S-1, F-1) · Registrants

Icosavax, Inc.

SEC CIK
1786255 · filings on EDGAR ↗
Registration
Form S-1, first filed 2021-07-07, last 2021-07-22; 1 initial registration, 1 amendment
Outcome
Final prospectus filed 2021-07-30; declared effective 2021-07-28
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
1930 BOREN AVE., SUITE 1000, Seattle, WA 98101
EDGAR entity type
operating
Insiders and CEO pay
Icosavax, Inc. on the corporate pages

Offering terms

Proposed price range
$14.00–$16.00 per share (S-1/A filed 2021-07-22)
Final price
$15.00 per share, within the range (424B4 filed 2021-07-30, an initial public offering)
Shares sold
12,133,333
Gross proceeds
$181,999,995 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol ICVX
Lead underwriters
Jefferies; Cowen (3,458,000 shares); Evercore (2,972,667 shares); William Blair (1,334,666 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
2021-07-07S-1S-1 (registration)Icosavax, Inc.0001193125-21-209031 ↗
2021-07-22S-1/AS-1/A (amendment)Icosavax, Inc.0001193125-21-221834 ↗
2021-07-28S-1MEFS-1MEF (added securities)Icosavax, Inc.0001193125-21-227732 ↗
2021-07-28EFFECTEFFECT (declared effective)Icosavax, Inc.9999999995-21-002961 ↗
2021-07-30424B4424B4 (final prospectus)Icosavax, Inc.0001193125-21-229444 ↗
2022-08-29EFFECTEFFECT (declared effective)Icosavax, Inc.9999999995-22-002540 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2021-07-22S-1/Aregistration statement$14.00–$16.0010,000,000-Nasdaq ICVX4primary document; range, shares headline, cover names 4document ↗
2021-07-30424B4final prospectus$15.0012,133,333$181,999,995Nasdaq ICVX4primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
ADAMS STREET PARTNERS LLCOther; TenPercentOwner22021
Cearley CassiaOfficer; OtherChief Business Officer182021–2024
Chen BihuaOther; TenPercentOwner22021
Cormorant Asset Management, LPOther; TenPercentOwner22021
Cormorant Global Healthcare Master Fund, LPOther; TenPercentOwner22021
Cormorant Private Healthcare Fund III LPOther; TenPercentOwner22021
FIELDS HEIDIDirector; Other52021–2024
Gould Terry PDirector; Director,TenPercentOwner22021
Holtzman DouglasOfficerChief Scientific Officer112021–2023
Kanesa-thasan NiranjanOfficer; OtherChief Medical Officer132021–2024
Kolchinsky PeterDirector,TenPercentOwner62021–2024
MCDADE MARKDirector; Other; TenPercentOwner62021–2024
NanoDimension III GP Limited PartnershipOther; TenPercentOwner22021
NanoDimension III, L.P.Other; TenPercentOwner22021
NanoDimension III Management LtdOther; TenPercentOwner22021
Nicholson JonathanOther; TenPercentOwner22021
Qiming U.S. Healthcare Fund II, L.P.Director,TenPercentOwner; Other22021
Qiming U.S. Healthcare GP II, LLCOther; TenPercentOwner22021
RA Capital Healthcare Fund LPDirector,TenPercentOwner62021–2024
RA CAPITAL MANAGEMENT, L.P.Director,TenPercentOwner62021–2024
RA Capital Nexus Fund II, L.P.Director,TenPercentOwner52021–2024
Richardson Charles EOfficerSee Remarks; SVP, Technical Operations52021–2022
Russo Thomas JosephOfficer; OtherChief Financial Officer112021–2024
SanofiTenPercentOwner22021
Shah Rajeev M.Director,TenPercentOwner62021–2024
Simpson Adam K.Director,Officer; OtherChief Executive Officer202021–2024
Veneman Ann MDirector; Other52021–2024
Yamada TadatakaDirector12021
Bekiroglu ElizabethOfficerGeneral Counsel & Corp. Sec.; See Remarks62021–2023
Shiver John W.Director; Other52022–2024
Wassil JimDirector; Other42022–2024
RA Capital Nexus Fund, L.P.Director,TenPercentOwner12023
Khan AminOfficer; OtherEVP, Head of Research & Dev.32023–2024

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2021-04-07Icosavax, Inc.Biotechnology$99,729,701$99,729,701361
2019-10-18Icosavax, Inc.Biotechnology$51,007,373$30,007,376221

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationIcosavax, Inc.WAState business registriesname and state
Business registrationIcosavax, Inc.WAState business registriesname and state
Form D issuerIcosavax, Inc.WAForm D private offeringsCIK (EXACT)
Patent assigneeICOSAVAX, INC.WAPatents (USPTO)name and state
SEC filerIcosavax, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerIcosavax, Inc.WATrademarks (USPTO)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), WA first:

More with this interest.

In other datasets, the same topic (Health) in WA:

Interests: Biological Products, (No Diagnostic Substances) · Health